Back to Top Skip to main content

Surgeons perform first bioengineered blood vessel transplant in military patient

Development of the Human Acellular Vessel, or HAV, starts by taking living cells from a human blood vessel and placing them onto a tube-shaped frame. These vascular cells are kept alive in an organ chamber, growing around the tube-shaped lattice. Over time, the lattice that was used to seed the original vascular cells dissolves, and scientists remove the original cells so the new vessel doesn’t cause an immune response when it’s implanted. What is left is a solid, tubular structure made of human vascular material that looks and acts like a blood vessel -- thus, the bio-engineered and newly-grown blood vessel, or HAV. (USU medical illustration by Sofia Echelmeyer) Development of the Human Acellular Vessel, or HAV, starts by taking living cells from a human blood vessel and placing them onto a tube-shaped frame. These vascular cells are kept alive in an organ chamber, growing around the tube-shaped lattice. Over time, the lattice that was used to seed the original vascular cells dissolves, and scientists remove the original cells so the new vessel doesn’t cause an immune response when it’s implanted. What is left is a solid, tubular structure made of human vascular material that looks and acts like a blood vessel -- thus, the bio-engineered and newly-grown blood vessel, or HAV. (USU medical illustration by Sofia Echelmeyer)

Recommended Content:

Research and Innovation | Technology

An Army veteran in danger of losing his leg from vascular disease has become the first patient in the Military Health System to undergo transplantation of a new type of bioengineered blood vessel thanks to surgeons from the Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center.

Air Force Col. (Dr.) Todd Rasmussen, professor of Surgery and associate dean for Clinical Research at USU, performed the surgery at Walter Reed-Bethesda this month after getting approval for use of an investigational product called the Human Acellular Vessel, or HAV, developed by Humacyte, Inc.

“Military surgeons have been following and researching this technology for a number of years as potentially a new way to repair blood vessel injury on the battlefield. We are excited to see the product come to fruition, and for our team to gain real-world experience with it in the operating room at Walter Reed. Our ability to use this product to save this patient’s leg is a credit to a partnership that included the military’s medical research program, Humacyte, and a forward-leaning approach by the Food and Drug Administration.”

The rate of vascular injury during the wars in Iraq and Afghanistan was higher than that reported during previous wars, and faced with this challenge, the Department of Defense was in search of an off-the-shelf biologic conduit that could be used to save the limbs of service members. Repair of a damaged blood artery would normally involve surgically removing and using an extra vein that runs just under the surface of the length of the patient’s inner leg called the saphenous. However, some patients may not have an adequate sized vein, or they may have had the vein damaged during the original injury; a common situation in blast-injured service members. Using the patient’s own saphenous vein for repair also increases the time of an already complex operation, and requires another surgical incision that has its own risks.

The HAV was created by a team of clinician-scientists from Yale and Duke Universities led by Drs. Laura Niklason and Jeff Lawson, respectively, and has only recently been used in hundreds of civilian patients in the U.S. and around the world, mostly on a research basis. In 2011, amidst several deployments and while serving as the deputy commander of the U.S. Army Institute of Surgical Research, Rasmussen had an opportunity to see how the HAV worked and was able to study it himself in an animal model of vascular injury. For nearly a decade, Rasmussen has led collaborative efforts to help bring this innovative technique into the Military Health System. Because the HAV does not yet have full FDA clearance, Rasmussen worked with members of the FDA to get his own approval to use the investigational device at Walter Reed. Rasmussen believes this procedure could soon be the new way to help save limbs on the battlefield.

“I think this product could be a game changer for the management of vascular injury and vascular disease – it could eliminate the need for saphenous vein harvest or use of plastic vascular conduits. We’ve been enthused by its potential use on the battlefield, studied it in our military labs and supported its research in civilian centers, and it’s great to see it now diffuse into real-world practice,” Rasmussen said. “Injury to major blood vessels of the body is the most common cause of death and disability in combat and we need new technologies such as this to improve our ability to save lives and limbs. Because this product is made of neutral biologic material, it has the potential to be resistant to infection and become incorporated or adopted by the recipient patient. The fact that it can be bio-manufactured to a specific size and available for immediate, off-the-shelf use is also revolutionary.”

Development of the HAV starts by taking living cells from a human blood vessel and placing them onto a tube-shaped frame. Just as cells would normally grow inside a petri dish, these vascular cells are kept alive in an organ chamber and allowed grow around the tube-shaped lattice. As the cells are maintained in the chamber they secrete the strong structural substances that make up a blood vessel. During the process, the chamber generates a pulsating rhythm through the tube-shaped frame, mimicking a heartbeat and giving the new vessel the sensation of blood pressure as it is forming. Over the course of weeks, the cells and the strong framework they form begin to “think and behave” like a real blood vessel, Rasmussen said. Over time, the lattice that was used to seed the original vascular cells dissolves, and scientists remove the original cells so the new vessel doesn’t cause an immune response when it’s implanted. What is left is a solid, tubular structure made of human vascular material, which looks and performs like a blood vessel – thus, the bio-engineered and newly grown blood vessel, or HAV.

The HAV is then removed from the organ chamber, packaged in sterile preservative fluid, and stored ready for surgical implantation into a patient with an injured or blocked blood vessel. When sewn in place in the operating room, the HAV reroutes and restores blood flow around the vascular blockage or injury.

Since the finished framework that makes up the HAV is immune-neutral, Rasmussen noted, patients do not have problems “taking” the transplanted vessel, meaning the recipient’s body does not reject the HAV that it might otherwise not recognize because it’s a biologic originating from someone else’s vascular cells. Also, because the vascular framework can conform to any tube-shaped lattice, these vessels could potentially be made into various shapes and sizes to meet an individual patient’s needs, he said.

“Once the HAV is implanted, the patient’s own cells circulate through and hopefully make themselves at home to ‘redecorate’ the new vessel as their own” Rasmussen said. “Although further research needs to be performed to understand the long-term durability and features of this product, the hope is that as the HAV functions in the recipient patient, it will become that patient’s own ‘living’ vessel and last indefinitely.

“Having this innovative product reach the point of clinical use and study is a great example of the synergies that exist between university-based innovation, private industry, the DoD-medical research program and the FDA. It’s another example of how priorities and the lessons learned from war propel advances in medicine and the biomedical sciences – hopefully to the betterment of military and civilian patients.”

Disclaimer: Re-published content may have been edited for length and clarity. Read original post.         

You also may be interested in...

DHA IPM 18-017: Military Health System (MHS) Information Technology (IT) Investment Management Framework

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (v), establishes Defense Health Agency's (DHA) procedures to: .Establish the overarching guidance to implement policies and procedures for managing DHA Deputy Assistant Director, Information Operations (DAD IO)/J-6Defense Health Program (DHP) IT resources. The DHA Investment Management Framework is used as an enabler for MHS leadership to make informed transparent financial decisions associated with the DHA DAD IO/J-6 systems, services, and capabilities and will continue to be used in the foreseeable future.

  • Identification #: 18-017
  • Date: 11/7/2020
  • Type: DHA Interim Procedures Memorandum
  • Topics: Technology

DHA IPM 18-015: Cybersecurity Program Management

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (c), and in accordance with the requirements of References (d) through (y): • Establishes the Defense Health Agency’s (DHA) procedures to implement and maintain a DHA Cybersecurity Program for the Military Health System (MHS) to protect and defend DHA information and Information Technology (IT). • Is effective immediately; it will be converted into DHA-Procedural Instruction (DHA-PI), “Cybersecurity Program Management.” This DHA-IPM will expire effective 12 months from the date of issue.

  • Identification #: 18-015
  • Date: 10/28/2020
  • Type: DHA Interim Procedures Memorandum
  • Topics: Technology

DHA IPM 18-007: Service Delivery Management Program

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (e): - Establishes the Defense Health Agency’s (DHA) procedures for implementing and managing high quality information technology (IT) services by the Chief Information Officer (CIO), Deputy Assistant Director Information Operations (DAD IO/J-6), Military Health System (MHS). The DHA Service Delivery Management program provides customers requesting IT services from the DAD IO/J-6 or Defense Information Systems Agency service catalogs with an on-demand, automated system that provides a single-entry point to submit service requests. The automated system enables DAD IO/J-6 to align business needs and use repeatable and scalable processes to holistically track, manage, and report on customer submitted requests for IT services from submission to fulfillment. - Is binding on DoD Components and supports the Director’s, DHA, responsibility to develop appropriate management models to maximize efficiencies in the activities carried out by the DHA. - This DHA-IPM is effective immediately; it will be converted into a DHA-Procedural Instruction (DHA-PI). This DHA-IPM will expire effective 12 months from the date of issue.

  • Identification #: 18-007
  • Date: 7/28/2020
  • Type: DHA Interim Procedures Memorandum
  • Topics: Technology

DHA IPM 18-016: DHA IPM 18 016 Medical Coding of the DoD Health Records

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (s): • Establishes the Defense Health Agency’s (DHA) procedures for centralized oversight, standardized operations, and ensured quality and performance for the coding of DoD Health Records. • This DHA-IPM is effective immediately; it will be converted into a DHA-Procedural Instruction. This DHA-IPM will expire 12 months from the date of issue.

DHA IPM 18-011: Video Network Center (VNC) Endpoint Standards

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (g): - Provides guidance for video network endpoint standards required for sites to connect to the Defense Health Agency (DHA) VNC network. These standards will help ensure security compliance, efficiency, and best practices are maintained across the DHA network. Meeting certification requirements brings many benefits, including: increased assurances of a successful video teleconference (VTC) experience, full access to bridge and point-to-point calls, and access to peer video networks, including the Department of Veterans Affairs, academia, and industry partners. Compliance with stated standards does not preclude users connecting to other DoD approved networks. - This DHA-IPM is effective immediately; it will be converted into a DHA-Procedural Instruction. This DHA-IPM will expire effective 12 months from the date of issue.

  • Identification #: 18-011
  • Date: 9/20/2019
  • Type: DHA Interim Procedures Memorandum
  • Topics: Technology

DHA IPM 18-013: Risk Management Framework (RMF)

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (ac): • Incorporates cybersecurity strategy, policy, awareness/training, assessment, continuous monitoring, authorization, implementation, and remediation. • Aligns with the Deputy Assistant Director, Information Operations (DAD IO) J-6/Chief Information Officer’s (CIO) key concept of increasing cybersecurity of Defense Health Agency’s (DHA) Information Technology (IT); therefore, robust risk assessment and management is required. • Encompasses lifecycle risk management to determine and manage the residual cybersecurity risk. • This DHA-IPM is effective immediately; it will be converted into a DHA-Procedural Instruction. This DHA-IPM will expire effective 12 months from the date of issue.

  • Identification #: 18-013
  • Date: 9/20/2019
  • Type: DHA Interim Procedures Memorandum
  • Topics: Technology

DHA-PI 3200.01: Research and Development (R&D) Enterprise Activity (EA)

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (p): a. Establishes the Defense Health Agency’s (DHA) procedures for the Deputy Assistant Director (DAD), R&D to manage and execute, on behalf of the Assistant Secretary of Defense for Health Affairs (ASD(HA)), the portion of the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation assigned to it (referred to as the “DHP Science and Technology (S&T) Program)”. The DHP S&T Program includes Budget Activities (BAs) 6.1-6.3 and 6.6. The ASD(HA) provides policy, direction, and guidance to inform planning, programming, budgeting, and execution of the DHP RDT&E appropriation in accordance with statute, regulation, and policy in Reference (a). The DAD-R&D, and Component Acquisition Executive (CAE) manage and execute DHP RDT&E Program funds aligned to them on behalf of the ASD(HA). The CAE is responsible for managing BAs 6.4, 6.5, and 6.7 funding, as well as Procurement and Operations and Maintenance funding required to support DHP-funded Acquisition Programs, regardless of acquisition activity. b. Supports the Director, DHA, in developing appropriate DHA management models to maximize efficiencies in the management and execution of DHP RDT&E-funded activities carried out by the Combatant Commands (CCMDs), Services, Uniformed Services University of the Health Sciences (USU), Defense Agencies, and other DoD Components, as applicable. c. Codifies processes to confirm DHP RDT&E funds are applied towards medical priorities and aligned to ASD(HA) policy, direction, and guidance to develop and deliver innovative medical products and solutions that increase the readiness of the DoD medical mission in accordance with Reference (a). d. Supports the following objectives of the R&D EA: (1) Increasing the quantity, quality, and pace of medical research through improved programmatic organization, processes, and oversight. (2) Ensuring DHP RDT&E funded efforts align to ASD(HA) published program guidance that provides resourcing guidance and translates national, departmental, and Service priorities into specific program objectives. (3) Verifying alignment of DHP RDT&E funds to medical priorities and to ASD(HA) policy, direction, and guidance to ensure the development and delivery of medical materiel and knowledge solutions. (4) Facilitating coordination with the CCMDs, Services, USU, Defense Agencies, and other DoD Components, as applicable, to ensure DHP RDT&E funded activities address joint medical capability gaps, and avoid unnecessary duplication.

DHA PI 3201.05: Technology Transfer (T2) Program

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI) based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (t), establishes responsibilities, procedures, and guidance for the Defense Health Agency’s (DHA) T2 program.

  • Identification #: 3201.05
  • Date: 6/20/2019
  • Type: DHA Procedural Instruction
  • Topics: Technology

DHA IPM 18-018: Physical Custody and Control of the DoD Health Record

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (p): • Establishes the Defense Health Agency’s (DHA) procedures for the physical custody and control of DoD Health Records at all DoD Military Treatment Facilities (MTFs) and the management, monitoring, review, and evaluation of DoD Health Record availability at MTFs. • This DHA-IPM is effective immediately and will expire effective 12 months from the date of issue. It must be incorporated into the forthcoming DHA-Procedural Instruction, “Health Records Management”.

DHA IPM 18-017: Military Health System (MHS) Information Technology (IT) Investment Management Framework

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (v), establishes Defense Health Agency’s (DHA) procedures to: • Establish the overarching guidance to implement policies and procedures for managing DHA Deputy Assistant Director, Information Operations (DAD IO)/J-6 Defense Health Program (DHP) IT resources. The DHA Investment Management Framework is used as an enabler for MHS leadership to make informed transparent financial decisions associated with the DHA DAD IO/J-6 systems, services, and capabilities and will continue to be used in the foreseeable future. • Provide full and total awareness of all IT across the enterprise ensuring all MHS healthcare-related IT investments are accounted for and integrated both operationally and financially. This includes all IT systems, applications, and devices and all their funding identified to manage a coherent and integrated healthcare capability across the enterprise. • Provide and supersede guidance and instructions previously provided through the Services. As Military Medical Treatment Facilities (MTFs) transition to DHA management and responsibility, procedures in this DHA-IPM will supersede IT systems guidance and instructions previously provided through the Services; including IT systems in all MTFs, clinics, and enterprise services provided to Other Lines-of-Business (OLB), such as training and research, etc. In addition, it supports a coherent and comprehensive catalog of IT capability investments encompassing all IT used to support the MHS mission. • Require that all funding sources, type and Budget Activity Group (BAG), purchasing or supporting any IT must be identified for inclusion in the DHA portfolio of IT capability investments. • Provide superseding guidance and instruction, through this DHA-IPM until a DHA-Procedural Instruction is issued previously provided by the Services in References (w) through (ad), for the MTFs as they are transitioned to DHA management and responsibility. • This DHA-IPM is effective immediately and it will be converted into a DHA-Procedural Instruction. This DHA-IPM will expire effective 12 months from the date of issue.

  • Identification #: 18-017
  • Date: 11/6/2018
  • Type: DHA Interim Procedures Memorandum
  • Topics: Technology

DHA PI 8140.01: Acceptable Use of Defense Health Agency Information Technology (IT) (Updated)

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (m), establishes the Defense Health Agency’s (DHA) procedures for acceptable use of DHA IT by authorized and privileged users.

  • Identification #: DHA PI 8140.01
  • Date: 10/16/2018
  • Type: DHA Procedural Instruction
  • Topics: Technology

Waiver of Restrictive Licensure and Privileging Procedures to Facilitate the Expansion of Telemedicine Services in the Military Health System 12-010

Policy

In order to facilitate the expansion of telemedicine services in the Military Health System, this memorandum waives selective provisions of Department of Defense 602S.13-R, "Clinical Quality Assurance in the Military Health System," June 11 , 2004. This waiver is conditioned on the specific provisions of this memorandum, and shall remain in effect, unless modified or revoked, until the cancellation and reissuance of DoD 602S.13-R, or the issuance of a Department of Defense Instruction for or including telemedicine.

MHS Enterprise Architecture Signed Memo and Guide 20120730

Policy

Announcement of the release of the Military Health System (MHS) Enterprise Architecture (EA) Guide. The guide supports the MHS CIO’s responsibilities for development and maintenance of EA, which complies with the Department of Defense’s responsibilities under the Clinger-Cohen Act of 1996, Public Law 104-106.

  • Identification #: 00-memo-2012-07-30
  • Date: 7/30/2012
  • Type: Memorandums
  • Topics: Technology

Guidance on the Establishment of a Human Cell, Tissue, and Cellular and Tissue Based Products Program

Policy

This memorandum requests the Services resource a Human Cell, Tissue, and Cellular and Tissue Based Products (HCT/Ps) Program that complies with regulatory standards for management and oversight of HCT/Ps, according to the best fit for their Service.

Standard Enterprise Architecture Requirements for Acquiring Information Management/Information Technology Products and Services

Policy

The Military Health System (MHS) Information Management/Information Technology (IM/IT) Strategic Plan established enterprise-wide interoperability and common architecture goals for MHS 1M/IT products and services that promote agility and interoperability within MHS and externally with Federal and industry partners.

  • Identification #: 00-memo-2012-06-19
  • Date: 6/19/2012
  • Type: Memorandums
  • Topics: Technology
<< < 1 2 > >> 
Showing results 1 - 15 Page 1 of 2

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.